| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705293 | Ophthalmology | 2017 | 12 Pages |
Abstract
The SCORE2 cohort is a heterogeneous population, including both CRVO and HRVO eyes and both treatment-naïve eyes and eyes treated previously with anti-VEGF, which will allow study results to have broad applicability to CRVO and HRVO patients receiving treatment for macular edema. Similarities of the baseline characteristics of the SCORE2 population to other CRVO trial cohorts will allow meaningful comparisons of outcome results across trials.
Keywords
Hemiretinal vein occlusionHRVONEI VFQ-25AMDiOpSD OCTBRVORVOCRVOETDRSfluorescein angiographyBranch retinal vein occlusionRetinal vein occlusionCentral retinal vein occlusionOctTAEOptical coherence tomographySpectral-domain optical coherence tomographyearly treatment diabetic retinopathy studytreat and extendage-related macular degenerationanti-VEGFVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressureScore
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Ingrid U. MD, MPH, Paul C. PhD, Michael S. MD, Barbara A. MD, Neal L. PhD, Maria MBA, Pravin U. MD, SCORE2 Investigator Group SCORE2 Investigator Group,